Tempus AI gains as BTIG lifts price target, cancer trial readthrough in focus
Tempus AI Inc. shares are trading higher Thursday after BTIG maintained a Buy rating and raised its price forecast to $80, while investors also focus on a Phase 3 cancer trial readthrough tied to the pending Personalis acquisition.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.